@RaceOncology - another timely announcement and interesting to see the links into HK (China) and now S.Korea!
A couple of quick questions:
1) The process to get ethics approval was very slow in Australia for the EMD AML trial. Do you expect the ethics/institutional approval in HK and S.Korea to be any quicker than Australia?
2) Subject to your answer, could we see the P1a trial kick off in HK/S.Korea first rather than Australia?
3) Are you eligible for the Australian R&D tax rebate for clinical studies conducted in HK/S.Korea?
4) This is the first time we've seen S.Korea mentioned, any reason why that market was attractive? Was Japan also a consideration?
Keep up the great work!
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220, page-18
-
- There are more pages in this discussion • 129 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $288.0M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.69 | $1.57 | $387.6K | 237.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 807 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 2376 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |